+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 640 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are investigating the use of 19F MRI, a novel imaging technique using inhaled perfluoropropane gas combined with magnetic resonance imaging, to visualize lung ventilation in children and adolescents aged 6 to 17 years. This method has not been studied in children before. The study compares children with cystic fibrosis who have normal lung function to healthy children of the same age to assess the feasibility of this imaging approach in a pediatric population. All participants will inhale perfluoropropane gas during MRI scans using two techniques standard breath hold and a newer free-breathing method that eliminates the need for breath holds. Each participant will breathe the gas for five breath hold cycles, with volume adjusted for lung size. This cross-sectional study includes both children with mild cystic fibrosis lung disease and healthy controls undergoing the same procedures. Participants will be evaluated during a single visit where they will undergo the MRI procedures along with spirometry and multiple breath nitrogen washout tests. Researchers will measure participation and completion rates as well as parental and child acceptability of the procedures. They will also analyze MRI-derived ventilation defect parameters and lung volumes to compare lung function between groups. The study aims to complete recruitment within two years, with assessments focused on the feasibility and sensitivity of these imaging and lung function measures.

Age: 6Years - 17YearsAll Genders
1 location
E

Actively Recruiting

Essential tremor ET is a common neurological condition that causes disabling tremors and can be hard to control with medications, which often have side effects limiting their use. This research aims to improve focused ultrasound ablation FUSA of the ventral intermediate nucleus Vim in the brain, a procedure approved for ET patients who do not respond well to medication. The study will compare the standard Vim-FUSA with an advanced approach using 3-D tractography, a brain imaging technique, to see if it improves treatment accuracy and safety. Researchers will also study how intraoperative magnetic resonance i-MR imaging can help monitor the procedure and predict outcomes. Participants will undergo the advanced 3-D tractography Vim-FUSA procedure, which involves shaving the head, attaching a stereotactic frame, positioning an ultrasound device, and using detailed imaging to target the brain area causing tremor. The treatment includes test sonications to explore the target, followed by therapeutic sonications to ablate the intended brain tissue. Participants will be assessed at baseline and again three months after the procedure to evaluate tremor changes and side effects. During the study, clinical tests and video assessments of tremor will be performed before and after treatment. Researchers will monitor for side effects during the procedure and for three months afterward. Outcomes measured include changes in tremor severity, quality of life related to tremor, participant satisfaction, and safety. The study involves 24 patients with moderate to severe ET who have not responded to medications. The total participation period includes baseline assessment and a three-month follow-up.

Age: 22Years +All GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and early effects of 4D-710, an investigational gene therapy, in adults with cystic fibrosis CF lung disease who cannot use or tolerate existing CFTR modulator therapies. A sub-study also includes adults with advanced CF lung disease or frequent lung flare-ups who are currently on CFTR modulator therapy. This Phase 12 open-label trial aims to find appropriate dosing and assess potential benefits for these patient groups. Participants receive a single inhaled dose of 4D-710, which is a gene therapy designed to deliver a corrected version of the CFTR gene to lung cells. The study includes a dose exploration phase for those ineligible for modulator therapy, a dose expansion phase at selected doses, and a sub-study for participants on modulator therapy receiving various doses. Each participant undergoes one administration of the therapy during the trial. Throughout the study, participants are monitored for adverse events over a 60-month period. Evaluations include lung function tests, oxygen saturation measurements, and tracking of pulmonary exacerbations. Participants maintain their existing treatments if applicable, and researchers assess safety and early signs of effectiveness. The total study duration extends up to approximately nine years, including long-term observation after dosing.

Age: 18Years +All GendersPhase 2
20 locations
S

Actively Recruiting

Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.

Age: 18Years +All GendersPhase 3
33 locations
E

Actively Recruiting

Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.

Age: 18Years +All GendersPhase 2
148 locations
E

Actively Recruiting

Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.

Age: 18Years +All GendersPhase 3
124 locations
S

Actively Recruiting

Researchers are evaluating a decisional support intervention called the University of Rochester-Geriatric Oncology assessment for Acute Myeloid Leukemia UR-GOAL compared to an attention control among older adults newly diagnosed with acute myeloid leukemia AML. This multicenter randomized controlled trial aims to assess whether UR-GOAL can reduce patient distress, improve shared decision making between patients, caregivers, and oncologists, and decrease decisional conflict. The study is sponsored by the University of Rochester and is conducted at four sites. Participants will be randomly assigned to one of two groups the UR-GOAL intervention or an attention control group. Patients in the UR-GOAL group will watch an AML-focused video, complete a best-worst scaling exercise to identify their care priorities, and receive a summary report to review and discuss during clinical visits. Caregivers, if available, will also watch the AML video and receive the summary report. Oncologists will receive a report summarizing the patients geriatric assessment, priorities, and prognosis perception. The control group patients and caregivers will watch a nutritional video, complete a nutrition questionnaire, and receive nutrition handouts for review and discussion. Oncologists in this arm will be provided with the patients nutrition questionnaire. Both arms involve reviewing these materials during upcoming clinical visits. Participants will be assessed at several time points including 1 month for distress, 2 weeks for shared decision making and decisional conflict, and observation of shared decision making at the start. All participants must be 60 years or older with a new AML diagnosis and have not started cancer-directed treatment except some temporary measures. The study involves questionnaires, videos, and discussions to measure decision-related outcomes. The total study duration extends to June 2030, with ongoing monitoring of patient distress and decision-making quality. Caregivers and oncologists also participate in aspects of the assessments and interventions.

Age: 60Years +All GendersPhase Not Applicable
4 locations
A

Actively Recruiting

Researchers are studying an experimental drug called REGN10597, given alone or with another drug called cemiplimab, in adults with advanced solid tumors such as melanoma and clear-cell renal-cell carcinoma. This Phase 12a trial aims to evaluate how safe, tolerable, and effective these study drugs are in treating cancers that have spread in the body. The study also explores side effects, drug levels in the blood, and whether the body produces antibodies against the drugs that might affect their activity or cause side effects. Participants receive REGN10597 alone or combined with cemiplimab in different dose levels to find the best dose for future studies. The study includes dose escalation and dose expansion phases, with separate groups for melanoma and renal-cell carcinoma patients. Dosing and administration follow the study protocol, and participants may have biopsies at screening and other times for research purposes. During the study, participants will be monitored closely for side effects and treatment responses. Researchers assess tumor response using established criteria and track various safety outcomes over approximately six years. Blood samples are collected to measure drug concentrations and antibody development. Participants will have regular visits for evaluations, and their health status will be followed for a long-term period to understand treatment effects and safety.

Age: 18Years +All GendersPhase 1Phase 2
11 locations
M

Actively Recruiting

Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease through a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study. The study includes a 40-week pivotal maintenance sub-study followed by a 240-week open-label extension sub-study, with a total duration of up to 286 weeks. Participants must have previously responded to treatment and completed endoscopy in a prior study phase. Participants receive subcutaneous injections of duvakitug or placebo according to the study protocol during the maintenance period. Those who complete the maintenance sub-study may continue in the open-label extension sub-study for longer-term treatment and monitoring. The treatment duration can be up to 280 weeks, including both study periods, with a total of up to 43 on-site visits planned. Throughout the trial, participants attend regular visits for assessments including clinical remission measured by the Crohns Disease Activity Index CDAI, endoscopic response, and patient-reported outcomes. Safety is monitored by tracking adverse events and antidrug antibody development. After treatment, participants have a 45-day follow-up visit. The study evaluates outcomes at Week 40 and continues monitoring throughout the extension period.

Age: 16Years - 80YearsAll GendersPhase 3
109 locations
S

Actively Recruiting

Researchers are evaluating whether adding infusions of a special type of immune cells called natural killer NK cells to the chemotherapy regimen gemcitabine and docetaxel GEMDOX can improve outcomes for children and young adults with sarcomas that have come back or did not respond to previous treatments. This study aims to determine the safety and effectiveness of this combined treatment in relapsed or refractory pediatric sarcomas, including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, and other soft tissue sarcomas. The study is a multi-center, phase 1 and 2 trial with ongoing safety and toxicity analysis conducted by Nationwide Childrens Hospital. Participants receive up to 8 cycles of treatment, each lasting 21 days. Each cycle includes intravenous gemcitabine on days 1 and 8, docetaxel on day 8, oral dexamethasone on days 7 to 9 to prevent side effects, pegfilgrastim on day 9 to help white blood cells recover, and intravenous TGF-beta imprinted TGFb2i, ex vivo expanded universal donor NK cells on day 12. Tumor response is checked after cycles 2, 4, 6, and 8. The study carefully monitors for toxicities related to the combined treatment and tracks how well the NK cells persist in the body and relate to clinical outcomes. During the trial, participants undergo regular assessments including tumor measurements using the RECIST 1.1 criteria every two cycles, evaluation of treatment-related side effects, and laboratory tests to monitor blood counts and organ function. Safety and disease progression are followed for 3 to 5 years. The study also evaluates six-month progression-free survival to understand how well the treatment controls the cancer. Overall, participants will be closely monitored throughout the study and during long-term follow-up to assess the treatments effects and safety.

Age: 2Years - 40YearsAll GendersPhase 1Phase 2
22 locations

1-10 of 640

1